PMID- 33989969
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1573-2517 (Electronic)
IS  - 0165-0327 (Linking)
VI  - 289
DP  - 2021 Jun 15
TI  - Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to 
      Antidepressant Therapy in Patients with Obesity or Overweight.
PG  - 167-176
LID - S0165-0327(21)00341-4 [pii]
LID - 10.1016/j.jad.2021.04.017 [doi]
AB  - There is significant association between obesity and depression. 
      Naltrexone/Bupropion (NB) is indicated for treatment of overweight and obesity 
      (BMI >/=27 kg/m(2) with a comorbidity or >/=30 kg/m(2)). This post-hoc analysis 
      examines safety and efficacy of NB and placebo among individuals with overweight 
      or obesity who were also taking antidepressant therapy during the LIGHT trial 
      (N=8910). Subjects were divided into four subgroups: NB + antidepressants 
      (n=1150), NB without antidepressants (n=3300), placebo + antidepressants (n=1127) 
      and placebo without antidepressants (n=3317). Among subjects taking NB, the 
      combined incidence of serious adverse events (AEs) and AEs leading to treatment 
      discontinuation was not significantly different between those on antidepressants 
      and those who were not. The key weight-loss efficacy analyses were performed on 
      NB or placebo-treated subjects who remained on study therapy through 104 weeks 
      and who did or did not have documented antidepressant use at each of the 
      baseline, week 52 and week 104 visits (Completers: N=1811; 47.0% female, 86.9% 
      white, mean age of 61 years, mean baseline BMI 37.4 kg/m(2)). The mean adjusted 
      weight change in subjects taking antidepressants was numerically, but not 
      significantly greater for NB vs. placebo (-6.3% vs. -4.3%). For those subjects 
      not on antidepressants, weight loss was significantly greater for NB vs. PL 
      (-6.8% vs. -3.6%). NB is generally well tolerated in patients with overweight or 
      obesity who are on antidepressants and is effective in promoting weight loss 
      regardless of antidepressant use. These results show that for patients on 
      antidepressant therapy, NB may be an effective option for obesity management.
CI  - Copyright (c) 2021. Published by Elsevier B.V.
FAU - McIntyre, Roger S
AU  - McIntyre RS
AD  - Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Electronic 
      address: roger.mcintyre@uhn.ca.
FAU - Paron, Emilia
AU  - Paron E
AD  - Bausch Health, Laval, QC, Canada.
FAU - Burrows, Melonie
AU  - Burrows M
AD  - Bausch Health, Laval, QC, Canada.
FAU - Blavignac, Jessica
AU  - Blavignac J
AD  - Bausch Health, Laval, QC, Canada.
FAU - Gould, Errol
AU  - Gould E
AD  - Currax Pharmaceuticals LLC, Morristown, NJ, USA.
FAU - Camacho, Fernando
AU  - Camacho F
AD  - University of Waterloo, Department of Statistics and Actuarial Sciences, Waterloo 
      ON, Canada.
FAU - Barakat, Maxime
AU  - Barakat M
AD  - Bausch Health, Laval, QC, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210423
PL  - Netherlands
TA  - J Affect Disord
JT  - Journal of affective disorders
JID - 7906073
RN  - 0 (Antidepressive Agents)
RN  - 01ZG3TPX31 (Bupropion)
RN  - 5S6W795CQM (Naltrexone)
SB  - IM
MH  - Antidepressive Agents/adverse effects
MH  - *Bupropion/adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Naltrexone/adverse effects
MH  - Obesity/drug therapy
MH  - Overweight/complications
MH  - Weight Loss
OTO - NOTNLM
OT  - Naltrexone / bupropion
OT  - SNRI
OT  - SSRI
OT  - antidepressant
OT  - obesity
OT  - weight loss
EDAT- 2021/05/15 06:00
MHDA- 2021/07/06 06:00
CRDT- 2021/05/14 20:21
PHST- 2020/09/01 00:00 [received]
PHST- 2021/02/08 00:00 [revised]
PHST- 2021/04/17 00:00 [accepted]
PHST- 2021/05/15 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2021/05/14 20:21 [entrez]
AID - S0165-0327(21)00341-4 [pii]
AID - 10.1016/j.jad.2021.04.017 [doi]
PST - ppublish
SO  - J Affect Disord. 2021 Jun 15;289:167-176. doi: 10.1016/j.jad.2021.04.017. Epub 
      2021 Apr 23.